<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">
  <title>PolyQ - SCA3</title>
  <link rel="shortcut icon" href="../../Images/image1.ico">
  <link rel="stylesheet" href="style_2.css">
  <link rel="stylesheet" href="highlight-js/highlightjs.css">
  <link rel="stylesheet" href="ScrollSpy.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.1.1/css/all.min.css" integrity="sha512-KfkfwYDsLkIlwQp6LFnl8zNdLGxu9YAA1QvwINks4PhcElQSvqcyVLLD9aMhXd13uQjoXtEKNosOWaZqXgel0g==" crossorigin="anonymous" referrerpolicy="no-referrer" />
  <link rel="stylesheet" href="int-image.css">
</head>
<body>
  <script src="ScrollSpy.min.js"></script>
  <script src="highlight-js/highlight.pack.js"></script>
    <header>
      <a href="https://abcri.pt/"><img class="abcri-logo" src="../../Images/Logo_ABCRI.png"></a>
      <a><img class="mngt-logo" src="../../Images/Logo_MNGT.png"></a>
      <h1> <strong>A ABC Research Institute polyglutamine disease database</strong></h1>
    </header>
  <nav>
    <img class="poly-logo" src="../../Images/logo-plyq.png"/>
    <ul>
      <li><a href="../hd">HD</a></li>
      <li><a href="../drpla">DRPLA</a></li>
      <li><a href="../sbma">SBMA</a></li>
    </ul>
      <div class="dropdown">
        <button onclick="myFunction()" class="dropbtn">More <i class="fa-solid fa-caret-down"></i></button>
        <div class="dropdown-content" id="myDropdown">
          <a href="../sca1">SCA1</a>
          <a href="../sca2">SCA2</a>
          <a href="../sca6">SCA6</a>
          <a href="../sca7">SCA7</a>
          <a href="../sca17">SCA17</a>
        </div>
      </div>
      <div class="dropdown-little">
        <button onclick="myFunctionLittle()" class="dropbtn-little">Other Diseases &nbsp <i class="fa-solid fa-turn-down"></i></button>
        <div class="dropdown-content-little" id="myDropdownLittle">
          <a href="../hd">HD</a>
          <a href="../drpla">DRPLA</a>
          <a href="../sbma">SBMA</a>
          <a href="../sca1">SCA1</a>
          <a href="../sca2">SCA2</a>
          <a href="../sca6">SCA6</a>
          <a href="../sca7">SCA7</a>
          <a href="../sca17">SCA17</a>
        </div>
      </div>
    <a href="../../home" class="return-button"><i class="fa-solid fa-house"></i> Return to Home page </a>
    <a href="../../home" class="return-little"><i class="fa-solid fa-house"></i> Home </a>
  </nav>
  <main>
    <div class="aside-bar-left">
      <h3> Page navigation</h3>
      <div id="indicator"></div>
    </div>
    <div class="text">
    <h1><a href="./"><i class="fa-solid fa-caret-right"></i> &nbspSpinocerebellar Ataxia 3</a></h1>
    <section class="scrollspy" spy-title="Introduction">
      <div class="intro-section">
        <h2> Introduction </h2>
        <p>
          Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an inherited disease of the central nervous system involving progressive ataxia. As is the case of many of the inherited ataxias, SCA3/MJD results from a specific genetic defect that leads to impairment of nerve cells in the brain and nerve fibers carrying messages to and from the brain.
        </p>
        <p>
          The symptoms of SCA3/MJD usually appear in middle adult life and progress over several decades, with some patients surviving for almost 30 years after the onset of symptoms. Onset in adolescence or as late as age 70 also can occur. This extreme range in age of onset reflects differences in the size of the disease-causing DNA repeat.
        </p>
        <p>
          SCA3/MJD is inherited in an autosomal dominant manner. Each child of a heterozygous affected individual has a 50% chance of inheriting the pathogenic mutation.
        </p>
      </div>
    </section>
    <section class="scrollspy" spy-title="First described">
      <div class="firstd-section">
      <h2> First Described</h2>
      <p>
        SCA3/MJD was originally described in members of the families of Machado, Thomas, and Joseph originating from São Miguel Island, Azores, Portugal, in 1972 <span class="refbig"><a href="#ref-one">[1]</a></span><span class="reflittle"><a href="#ref-one-little">[1]</a></span>.
      </p>
      <p>
        In 1980, it was named Machado-Joseph disease, honouring the first patients and descendants who suffered from the disease <span class="refbig"><a href="#ref-two">[2]</a></span><span class="reflittle"><a href="#ref-two-little">[2]</a></span>.
      </p>
      <p>
        Researchers first described it as SCA3/MJD in 1983.
      </p>
     </div>
    </section>
    <section class="scrollspy" spy-title="Epidemiology">
      <div class="epi-section">
        <h2> Epidemiology</h2>
        <p>
          Prevalence is estimated to be 1-2 in 100,000 with significant geographical and ethnic variations. Worldwide, SCA3/MJD is thought to be the most common spinocerebellar ataxia (SCA), comprising 20%-50% of families <span class="refbig"><a href="#ref-three">[3]</a></span><span class="reflittle"><a href="#ref-three-little">[3]</a></span>.
        </p>
        <p>
          Among SCAs, the relative frequency of SCA3/MJD is higher in countries such as Brazil (69-92%), Portugal (58-74%), Singapore (53%), China (48-49%), the Netherlands (44%), Germany (42%), and Japan (28-63%)  <span class="refbig"><a href="#ref-four">[4]</a></span><span class="reflittle"><a href="#ref-four-little">[4]</a></span>,
          <span class="refbig"><a href="#ref-five">[5]</a></span><span class="reflittle"><a href="#ref-five-little">[5]</a></span>. It is relatively less frequent in Canada (24%), United States (21%), Mexico (12%), Australia (12%), and India (5-14%), and it is considered as relatively rare in South Africa (4%) and Italy (1%) <span class="refbig"><a href="#ref-four">[4]</a></span><span class="reflittle"><a href="#ref-four-little">[4]</a></span>,
          <span class="refbig"><a href="#ref-five">[5]</a></span><span class="reflittle"><a href="#ref-five-little">[5]</a></span> <a href="#epi-img"></a>
        </p>
        <input type="checkbox" id="zoomCheck">
        <label for="zoomCheck">
          <img id="epi-img" src="../../Images/original images/SCA3/sca3_epi.png">
        </label>
      <figcaption> <strong>Figure 1:</strong> : Epidemiological features of spinocerebellar ataxia type 3 (SCA3). Relative frequency of SCA3 in the context of autosomal dominant cerebellar ataxias, around the world, according to Gene Reviews <span class="refbig"><a href="#ref-four">[4]</a></span><span class="reflittle"><a href="#ref-four-little">[4]</a></span>. Created with <a href="https://www.mapchart.net/">MapChart</a>.</figcaption>
        <a class="download-image" href="../../Images/original images/SCA3/SCA3_epi.png" download> [Fullsize image] </a>
      </div>
    </section>
    <section class="scrollspy" spy-title="Causative gene">
        <div class="gene-section">
          <h2> Causative gene</h2>
          <p>
            The gene associated with SCA3/MJD is denominated ATXN3. It has a size of around 42 kb with a minus strand orientation. The gene has 11 exons, according to many sources and the pathological CAG repeats are found within exon 10 <span class="refbig"><a href="#ref-six">[6]</a></span><span class="reflittle"><a href="#ref-six-little">[6]</a></span>(<a href="#gene-image1">Figure 2</a>). It is located on chromosome 14 (cytogenic band: 14q32.12, <a href="#gene-image2">Figure 3</a>).
          </p>
          <p>
            The mutation causing SCA3 is a translated CAG repeat expansion in ATXN3. The repeat length of the SCA3 gene in normal individuals varies between 12 and 44 trinucleotides, SCA3 patients have one allele within a range of 53 to 87 repeat units. Expanded SCA3 alleles display intergenerational instability with a tendency to further expansion.
          </p>
          <div class="image-one">
            <img id="gene-image1" src="../../Images/original images/SCA3/ATXN3.png" title="ATXN3 gene">
            <figcaption> <strong>Figure 2:</strong> ATXN3 gene with ranges of the CAG repeats necessary for disease and range in healthy individuals along with information about the total coding exons, chromosome location and size in DNA bases. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
            <a class="download-image" target="_blank" href="../../Images/original images/SCA3/ATXN3.png" download> [Fullsize image] </a>
          </div>
          <div class="image-two">
            <img id="gene-image2" src="../../Images/original images/SCA3/chromosome.png" title="ATXN3 gene chromosomal location">
            <figcaption> <strong>Figure 3:</strong> ATXN3 gene chromossomal band localization. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
            <a class="download-image" target="_blank" href="../../Images/original images/SCA3/chromosome.png" download> [Fullsize image] </a>
          </div>
        </div>
    </section>
    <section class="scrollspy" spy-title="Codified protein">
      <div class="protein-section">
        <h2> Codified protein: structure, domains, functions and intracellular localization</h2>
        <h3>Structure and domains</h3>
        <p>
          The ATXN3 gene codifies a protein named ataxin-3. Ataxin-3 has 361 amino acids (in its isoform 2), 41250 Da, and is widely expressed throughout the organism <span class="refbig"><a href="#ref-seven">[7]</a></span><span class="reflittle"><a href="#ref-seven-little">[7]</a></span>. A simple protein representation is represented in <a href="#protein-image">Figure 4</a>.
        </p>
        <p>
           An ataxin-3 protein representation is shown in <a href="#protein-image">Figure 4</a> along with <a href="#table">Table 1</a> with information on each important domain (information from <a href="https://www.uniprot.org/">Uniprot.org</a>).
        </p>
        <div class="non-interactive">
          <img id="protein-image" src="../../Images/original images/SCA3/ATXN3 protein.png" title="Ataxin-3 structure">
          <figcaption> <strong>Figure 4: </strong> Ataxin-3 protein structure. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
          <a class="download-image" target="_blank" href="../../Images/original images/SCA3/ATXN3 protein.png" download> [Fullsize image] </a>
        </div>
        <div class="table">
        <table style="width:100%" id="table">
          <caption>Table 1. &nbspAtaxin-3 domains</caption>
          <tr>
            <th>Description</th>
            <th>Position</th>
            <th>Length</th>
          </tr>
          <tr>
            <td>Josephin</td>
            <td>1-180</td>
            <td>180</td>
          </tr>
          <tr>
            <td>UIM1</td>
            <td>224-243</td>
            <td>20</td>
          </tr>
          <tr>
            <td>UIM2</td>
            <td>244-263</td>
            <td>20</td>
          </tr>
          <tr>
            <td>UIM3</td>
            <td>331-349</td>
            <td>19</td>
          </tr>
        </table>
        <div class="caption-under"> <strong>Table Caption:</strong> Ataxin-3 important domains with respective position within the protein structure and lengths.</div>
      </div>
      <h3>Protein functions and biological role</h3>
      <p>
        Ataxin-3 is part of many important cellular processes:
      </p>
      <ul>
        <li>Involved in the destruction and excess removal of damaged proteins through the cellular cleaning process: ubiquitin-proteasome system (UPS).</li>
        <li>It has specific deubiquitinase activity by linking certain lysines (lys48 and lys63) <span class="refbig"><a href="#ref-eight">[8]</a></span><span class="reflittle"><a href="#ref-eight-little">[8]</a></span>, and ubiquitin proteins
        <span class="refbig"><a href="#ref-nine">[9]</a></span><span class="reflittle"><a href="#ref-nine-little">[9]</a></span>,
        <span class="refbig"><a href="#ref-ten">[10]</a></span><span class="reflittle"><a href="#ref-ten-little">[10]</a></span>.</li>
        <li>Ataxin-3 is also capable of binding ATPases <span class="refbig"><a href="#ref-eleven">[11]</a></span><span class="reflittle"><a href="#ref-eleven-little">[11]</a></span> and identical proteins and can also acts as a transcriptional corepressor
        <span class="refbig"><a href="#ref-twelve">[12]</a></span><span class="reflittle"><a href="#ref-twelve-little">[12]</a></span>.</li>
        <li>Ataxin-3 is involved in nervous system development, actin, intermediate filament and microtubule cytoskeleton organization <span class="refbig"><a href="#ref-thirteen">[13]</a></span><span class="reflittle"><a href="#ref-thirteen-little">[13]</a></span>.</li>
        <li>It has a role in chemical synaptic transmission <span class="refbig"><a href="#ref-fourteen">[14]</a></span><span class="reflittle"><a href="#ref-fourteen-little">[14]</a></span>.</li>
        <li>Aids nuclear excision repair <span class="refbig"><a href="#ref-fifteen">[15]</a></span><span class="reflittle"><a href="#ref-fifteen-little">[15]</a></span>.</li>
      </ul>
      <h3> Protein intracellular localization</h3>
      <p>
        Ataxin-3 is found in the nucleus and the nucleus matrix where it performs some of its molecular functions  <span class="refbig"><a href="#ref-sixteen">[16]</a></span><span class="reflittle"><a href="#ref-sixteen-little">[16]</a></span>. It also localizes to the cytoplasm in many cases
        <span class="refbig"><a href="#ref-seventeen">[17]</a></span><span class="reflittle"><a href="#ref-seventeen-little">[17]</a></span>.
      </p>
      <div class="interactive-image" id="my-interactive-image">
        <img src="../../Images/cell-scheme.jpg" />
      </div>
      <div class="int-caption"> <strong>Figure 5:</strong> Ataxin-3 protein localization.<br>(Refresh this element if changed resolutions &nbsp<a href="javascript:void(0)" onclick="window.location.reload();"><i class="fa-solid fa-arrows-rotate"></i></a>&nbsp)</div>
      </div>
    </section>
    <section class="scrollspy" spy-title="Pathophysiology">
      <div class="patho-section">
        <h2> Pathophysiology</h2>
        <p>
          Ataxin-3 has some critical roles within the cell and it has been presented that the overexpression of normal ataxin‐3 prevents polyglutamine‐induced neurodegeneration, suggesting loss of normal ataxin‐3 action contributes to the pathogenesis of SCA3 <span class="refbig"><a href="#ref-twelve">[12]</a></span><span class="reflittle"><a href="#ref-twelve-little">[12]</a></span>.
        </p>
        <p>
          One of the most known pathogenic mechanism across many polyglutamine diseases, misfolding and aggregation. Expansion of the polyglutamine tract (polyQ) often leads to protein misfolding and aggregation. There are various hypotheses when it comes to aggregation and formation of inclusions. These aggregates and formation of inclusions can be seen as a protective cellular mechanism <span class="refbig"><a href="#ref-eighteen">[18]</a></span><span class="reflittle"><a href="#ref-eighteen-little">[18]</a></span>,
          <span class="refbig"><a href="#ref-nineteen">[19]</a></span><span class="reflittle"><a href="#ref-nineteen-little">[19]</a></span>. On the other hand, these aggregates have been presented and implicated in further disease development since they are able to sequester other normal functioning proteins and compromise cell functions
          <span class="refbig"><a href="#ref-twenty">[20]</a></span><span class="reflittle"><a href="#ref-twenty-little">[20]</a></span> -
          <span class="refbig"><a href="#ref-twenty-three">[23]</a></span><span class="reflittle"><a href="#ref-twenty-three-little">[23]</a></span>. A few studies have tried to link these aggregates to axonal impairment since some patients have shown metabolic abnormalities in white matter suggesting neuronal  and axonal dysfunction
          <span class="refbig"><a href="#ref-twenty-four">[24]</a></span><span class="reflittle"><a href="#ref-twenty-four-little">[24]</a></span>.
        </p>
        <p>
          In MJD/SCA3, there are known implicated cellular functions compromised.
        </p>
        <p>
          Protein homeostasis is one of the cellular functions that is found mostly perturbed/altered in MJD/SCA3. Protein quality control (PQC) systems such as the ubiquitin proteasome system (UPS) , molecular chaperones, and autophagy are disturbed in MJD/SCA3 <span class="refbig"><a href="#ref-twenty-three">[23]</a></span><span class="reflittle"><a href="#ref-twenty-three-little">[23]</a></span>. In these diseases, a consequence of continually producing aggregate-prone proteins is that PQC pathways may fail to keep pace.
        </p>
        <p>
          There are links between SCA3 and autophagy. In SCA3 disease brain levels of key autophagy proteins are dysregulated. Intriguingly, ataxin-3 appears to be directly tied to autophagy. A study has shown that ataxin-3 binds to and regulates levels of Beclin1, a key protein within the autophagy pathway involved in nucleation of autophagosomes <span class="refbig"><a href="#ref-twenty-five">[25]</a></span><span class="reflittle"><a href="#ref-twenty-five-little">[25]</a></span>.
        </p>
        <p>
          Compromised DNA repair also contributes to SCA3 disease pathogenesis. Normal and polyQ-expanded ataxin-3 are both rapidly recruited to DNA damage foci in cells exposed to genotoxic stress, though it remains unclear what mediates ataxin-3 nuclear import and translocation to damaged chromatin <span class="refbig"><a href="#ref-twenty-six">[26]</a></span><span class="reflittle"><a href="#ref-twenty-six-little">[26]</a></span>. Expression of polyQ-expanded mutant ataxin-3 also decreases DNA repair efficiency and enhances vulnerability of cells to toxins.
        </p>
        <p>
          Mitochondrial dysfunction has also been observed in MJD/SCA3. Studies have shown that the expression of mutant ataxin-3 may promote cell death mediated by mitochondria, lead to increased oxidative stress and less functioning mitochondria <span class="refbig"><a href="#ref-twenty-seven">[27]</a></span><span class="reflittle"><a href="#ref-twenty-seven-little">[27]</a></span> -
          <span class="refbig"><a href="#ref-twenty-nine">[29]</a></span><span class="reflittle"><a href="#ref-twenty-nine-little">[29]</a></span>.
        </p>
        <p>
          Calcium homeostasis deregulation has also been presented as a possible pathophysiological mechanism to MJD/SCA3. Mutant ataxin-3 alters calcium homeostasis since it binds and interacts with different targets that normal ataxin-3 usually doesn’t <span class="refbig"><a href="#ref-thirty">[30]</a></span><span class="reflittle"><a href="#ref-thirty-little">[30]</a></span>,
          <span class="refbig"><a href="#ref-thirty-one">[31]</a></span><span class="reflittle"><a href="#ref-thirty-one-little">[31]</a></span>. These interactions often lead to intracellular calcium overloads which in turn can lead to cell death by cytotoxic mechanisms
          <span class="refbig"><a href="#ref-thirty-two">[32]</a></span><span class="reflittle"><a href="#ref-thirty-two-little">[32]</a></span>.
        </p>
        <img id="patho-img" src="../../Images/original images/SCA3/SCA3.png" title="SCA3 pathogenic mechanisms">
        <div class="caption-patho"> <strong>Figure 6:</strong> SCA3 pathogenesis. A - Aggregates of misfolded ataxin-3 are found along with nuclear inclusion in neuronal cells of SCA3 patients (as it occurs in many other polyglutamine diseases). B - 1. PolyQ ataxin-3 has been shown to be involved in mytochondrial dysfunction since it increases oxidative stress and interferes with normal mitochondria function. 2. Ataxin-3 is very important for the PQC systems. Mutated ataxin-3 does not perform its normal functions and these systems may become compromised overtime. 3. Ataxin-3 can also be recruited to aid in DNA damage repair. Mutated forms cannot complete this task. 4. PolyQ ataxin-3 interacts with "not usual ataxin-3" targets that are involved in calcium homeostasis and therefore the calcium levels increase.</div>
        <a class="download-image" target="_blank" href="../../Images/original images/SCA3/SCA3.png" download> [Fullsize image] </a>
      </div>
    </section>
    <section class="scrollspy" spy-title="Clinical manifestations">
      <div class="clinical-section">
        <h2> Clinical manifestations: neuropathology, other signs and symptoms</h2>
        <h3>Neuropathology</h3>
        <p>
          The dentate nucleus of the cerebellum and substantia nigra are usually the most affected in SCA3/MJD, and these lesions account for the ataxic Parkinsonian phenotypes, respectively. Lesions of motor nuclei in the brain stem cause the complex disturbance of ocular motility and weakness of the tongue. Atrophy of the basis pontis is common, and polyglutamine-positive neuronal intranuclear inclusion bodies are most readily found in the pontine gray <span class="refbig"><a href="#ref-thirty-three">[33]</a></span><span class="reflittle"><a href="#ref-thirty-three-little">[33]</a></span>. Abnormalities of basal ganglia, thalamus, spinal cord, dorsal root ganglia, and sensory peripheral nerves are more variable
          <span class="refbig"><a href="#ref-thirty-three">[33]</a></span><span class="reflittle"><a href="#ref-thirty-three-little">[33]</a></span>.
        </p>
        <h3> Signs and symptoms</h3>
        <div class="list-flex">
          <div class="column-one">
            <div class="column-one-title">
              <strong>Early symptoms</strong>
            </div>
          <ul>
            <li>Loss of balance</li>
            <li>Gait abnormality</li>
            <li>Speech difficulties</li>
          </ul>
          </div>
          <div class="column-two">
            <div class="column-two-title">
              <strong>As disease progresses</strong>
            </div>
          <ul>
            <li>Spasticity</li>
            <li>Rigidity</li>
            <li>Loss of muscle bulk</li>
            <li>Slowness of movement</li>
          </ul>
          </div>
      </div>
      <p>
        In general, SCA3/MJD symptoms tend to be more wide-ranging than those in many other forms of ataxia <span class="refbig"><a href="#ref-thirty-four">[34]</a></span><span class="reflittle"><a href="#ref-thirty-four-little">[34]</a></span>.
      </p>
      <p>
        Other symptoms may be present, such as: a pyramidal syndrome with brisk deep tendon reflexes, peripheral neuropathy with amyotrophy; oculomotor abnormalities with nystagmus, eyelid retraction, progressive external ophthalmoplegia (PEO), ophthalmoparesis, bulging eyes; facial and lingual fasciculation; extrapyramidal signs, including dystonia; as well as weight loss and sleep disorders <span class="refbig"><a href="#ref-thirty-five">[35]</a></span><span class="reflittle"><a href="#ref-thirty-five-little">[35]</a></span>.
      </p>
      </div>
    </section>
    <section class="scrollspy" spy-title="References" id="references">
      <div class="reference-section">
        <h2> References </h2>
        <ol>
          <li><a id="ref-one-little" class="articlebottom">A. T. Meira, J. L. Pedroso, F. Boller, G. L. Franklin, O. G. P. Barsottini, and H. A. G. Teive, “Reconstructing the History of Machado-Joseph Disease,” Eur. Neurol., vol. 83, no. 1, pp. 99–104, May 2020.</a><br><a href="https://www.karger.com/Article/FullText/507191" class="links">[Karger - Full Text]</a></li>
          <li><a id="ref-two-little" class="articlebottom">L. Lima and P. Coutinho, “Clinical criteria for diagnosis of Machado‐Joseph disease,” Neurology, vol. 30, no. 3, pp. 319–319, Mar. 1980.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/7189034/" class="links">[PUBMED]</a><a href="https://n.neurology.org/content/30/3/319" class="links">[Neurology]</a></li>
          <li><a id="ref-three-little" class="articlebottom">T. Klockgether, C. Mariotti, and H. L. Paulson, “Spinocerebellar ataxia,” Nat. Rev. Dis. Prim., vol. 5, no. 1, Dec. 2019.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/30975995/" class="links">[PUBMED]</a><a href="https://www.nature.com/articles/s41572-019-0074-3" class="links">[Nature]</a></li>
          <li><a id="ref-four-little" class="articlebottom">H. Paulson and V. Shakkottai, “Spinocerebellar Ataxia Type 3,” GeneReviews®, Jun. 2020, Accessed: Mar. 08, 2022. [Online]. Available:</a><br><a href="https://www.ncbi.nlm.nih.gov/books/NBK1196/" class="links">[NCBI Books]</a></li>
          <li><a id="ref-five-little" class="articlebottom">C. N. C. Matos, L. Pereira de Almeida, “Polyglutamine Disorders,” J. Neurochem., vol. 1049, no. September, pp. 255–273, 2018.</a><br><a href="https://link.springer.com/book/10.1007/978-3-319-71779-1" class="links"></a></li>
          <li><a id="ref-six-little" class="articlebottom">C. Bettencourt and M. Lima, “Machado-Joseph disease: From first descriptions to new perspectives,” Orphanet J. Rare Dis., vol. 6, no. 1, 2011.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123549/" class="links">[PUBMED Central - Full Text]</a><a href="https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-6-35" class="links">[BMC - Full Text]</a></li>
          <li><a id="ref-seven-little" class="articlebottom">M. M. Evers, L. J. A. Toonen, and W. M. C. Van Roon-Mom, “Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies,” Mol. Neurobiol., vol. 49, no. 3, p. 1513, 2014.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012159/" class="links">[PUBMED Central - Full Text]</a><a href="https://link.springer.com/article/10.1007/s12035-013-8596-2" class="links">[Springer - Full Text]</a></li>
          <li><a id="ref-eight-little" class="articlbottoms">M. N. Laço, L. Cortes, S. M. Travis, H. L. Paulson, and A. C. Rego, “Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3,” PLoS One, vol. 7, no. 9, Sep. 2012.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435318/" class="links">[PUBMED Central - Full Text]</a><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043563" class="links">[PLOS One - Full Text]</a></li>
          <li><a id="ref-nine-little" class="articlebottom">J. J. Bai, S. S. Safadi, P. Mercier, K. R. Barber, and G. S. Shaw, “Ataxin-3 is a multivalent ligand for the parkin Ubl domain,” Biochemistry, vol. 52, no. 42, pp. 7369–7376, Oct. 2013.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807529/" class="links">[PUBMED Central - Full Text]</a><a href="https://pubs.acs.org/doi/10.1021/bi400780v" class="links">[ACS - Full Text]</a></li>
          <li><a id="ref-ten-little" class="articlebottom">K. M. Bernardi, J. M. Williams, T. Inoue, A. Schultz, and B. Tsai, “A deubiquitinase negatively regulates retro-translocation of nonubiquitinated substrates,” Mol. Biol. Cell, vol. 24, no. 22, pp. 3545–3556, Nov. 2013.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826992/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.molbiolcell.org/doi/10.1091/mbc.E13-06-0332?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed" class="links">[MBoC - Full Text]</a></li>
          <li><a href="" id="ref-eleven-little" class="articlebottom">Q. Wang, A. Li, and Y. Ye, “Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3,” J. Cell Biol., vol. 174, no. 7, pp. 963–971, Sep. 2006.</a><br><a href="https://rupress.org/jcb/article/174/7/963/44580/Regulation-of-retrotranslocation-by-p97-associated" class="links">[JCB - Full Text]</a></li>
          <li><a id="ref-twelve-little" class="articlebottom">T. Klockgether, “Ataxias,” Textb. Clin. Neurol. Third Ed., pp. 765–780, Jan. 2007.</a><br><a href="https://www.sciencedirect.com/science/article/abs/pii/S1353802008700361" class="links">[ScienceDirect]</a></li>
          <li><a id="ref-thirteen-little" class="articlebottom">A. J. Rodrigues et al., “Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death,” Biochim. Biophys. Acta, vol. 1803, no. 10, pp. 1154–1163, Oct. 2010.</a><br><a href="https://www.sciencedirect.com/science/article/pii/S0167488910001989?via%3Dihub" class="links">[ScienceDirect - Full Text]</a></li>
          <li><a id="ref-fourteen-little" class="articlebottom">L. Schöls, A. M. M. Vieira-saecker, S. Schöls, H. Przuntek, J. T. Epplen, and O. Riess, “Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients,” Hum. Mol. Genet., vol. 4, no. 6, pp. 1001–1005, Jun. 1995.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/7655453/" class="links">[PUBMED]</a><a href="https://academic.oup.com/hmg/article-abstract/4/6/1001/627632?redirectedFrom=fulltext" class="links">[Oxford Academic]</a></li>
          <li><a id="ref-fifteen-little" class="articlebottom">G. H. Wang, N. Sawai, S. Kotliarova, I. Kanazawa, and N. Nukina, “Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B,” Hum. Mol. Genet., vol. 9, no. 12, pp. 1795–1803, 2000.</a><br><a href="https://academic.oup.com/hmg/article/9/12/1795/578314" class="links">[Oxford Academic]</a></li>
          <li><a id="ref-sixteen-little" class="articlebottom">D. Tait et al., “Ataxin-3 is transported into the nucleus and associates with the nuclear matrix,” Hum. Mol. Genet., vol. 7, no. 6, pp. 991–997, Jun. 1998.</a><br><a href="https://academic.oup.com/hmg/article/7/6/991/2896786?login=false" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-seventeen-little" class="articlebottom">S. Macedo-Ribeiro, L. Cortes, P. Maciel, and A. L. Carvalho, “Nucleocytoplasmic Shuttling Activity of Ataxin-3,” PLoS One, vol. 4, no. 6, p. e5834, Jun. 2009.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688764/" class="links">[PUBMED Central - Full Text]</a><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005834" class="links">[PLOS One - Full Text]</a></li>
          <li><a id="ref-eighteen-little" class="articlebottom">M. Arrasate, S. Mitra, E. S. Schweitzer, M. R. Segal, and S. Finkbeiner, “Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death,” Nature, vol. 431, no. 7010, pp. 805–810, Oct. 2004.</a><br><a href="https://www.nature.com/articles/nature02998" class="links">[Nature - Full Text]</a></li>
          <li><a id="ref-nineteen-little" class="articlebottom">C. A. Ross and M. A. Poirier, “Protein aggregation and neurodegenerative disease,” Nat. Med., vol. 10 Suppl, no. 7, p. S10, 2004.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/15272267/" class="links">[PUBMED]</a><a href="https://www.nature.com/articles/nm1066" class="links">[Nature]</a></li>
          <li><a id="ref-twenty-little" class="articlebottom">H. Olzscha et al., “Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions,” Cell, vol. 144, no. 1, pp. 67–78, Jan. 2011.</a><br><a href="https://www.cell.com/cell/fulltext/S0092-8674(10)01372-3" class="links">[Cell - Full Text]</a></li>
          <li><a id="ref-twenty-one-little" class="articlebottom">A. McCampbell et al., “CREB-binding protein sequestration by expanded polyglutamine,” Hum. Mol. Genet., vol. 9, no. 14, pp. 2197–2202, Sep. 2000.</a><br><a href="https://academic.oup.com/hmg/article/9/14/2197/614727" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-twenty-two-little" class="articlebottom">H. L. Paulson et al., “Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3,” Neuron, vol. 19, no. 2, pp. 333–344, 1997.</a><br><a href="https://www.sciencedirect.com/science/article/pii/S0896627300809435" class="links">[ScienceDirect - Full Text]</a></li>
          <li><a id="ref-twenty-three-little" class="articlebottom">H. S. McLoughlin, L. R. Moore, and H. L. Paulson, “Pathogenesis of SCA3 and implications for other polyglutamine diseases,” Neurobiol. Dis., vol. 134, p. 104635, Feb. 2020.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980715/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.sciencedirect.com/science/article/pii/S0969996119303109?via%3Dihub" class="links">[ScienceDirect - Full Text]</a></li>
          <li><a id="ref-twenty-four-little" class="articlebottom">A. D’Abreu, M. C. França, H. L. Paulson, and I. Lopes-Cendes, “Caring for Machado-Joseph disease: current understanding and how to help patients,” Parkinsonism Relat. Disord., vol. 16, no. 1, pp. 2–7, Jan. 2010.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818316/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a id="ref-twenty-five-little" class="articlebottom">A. Ashkenazi et al., “Polyglutamine tracts regulate beclin 1-dependent autophagy,” Nature, vol. 545, no. 7652, pp. 108–111, May 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420314/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a id="ref-twenty-six-little" class="articlebottom">A. Pfeiffer et al., “Ataxin-3 consolidates the MDC1-dependent DNA double-strand break response by counteracting the SUMO-targeted ubiquitin ligase RNF4,” EMBO J., vol. 36, no. 8, pp. 1066–1083, Apr. 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391139/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.embopress.org/doi/full/10.15252/embj.201695151" class="links">[EMBOpress - Full Text]
          </a></li>
          <li><a id="ref-twenty-seven-little" class="articlebottom">A. H. Chou et al., “Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL,” Neurobiol. Dis., vol. 21, no. 2, pp. 333–345, Feb. 2006.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/16112867/" class="links">[PUBMED]</a><a href="https://www.sciencedirect.com/science/article/abs/pii/S0969996105002123?via%3Dihub" class="links">[ScienceDirect]</a></li>
          <li><a id="ref-twenty-eight-little" class="articlebottom">H. F. Tsai, H. J. Tsai, and M. Hsieh, “Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells,” Biochem. Biophys. Res. Commun., vol. 324, no. 4, pp. 1274–1282, Nov. 2004.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/15504352/" class="links">[PUBMED]</a><a href="https://www.sciencedirect.com/science/article/abs/pii/S0006291X04022223?via%3Dihub" class="links">[ScienceDirect]</a></li>
          <li><a id="ref-twenty-nine-little" class="articlebottom">Y. C. Yu, C. L. Kuo, W. L. Cheng, C. S. Liu, and M. Hsieh, “Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease,” J. Neurosci. Res., vol. 87, no. 8, pp. 1884–1891, 2009.</a><br><a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/jnr.22011" class="links">[Wiley Online Library]</a></li>
          <li><a id="ref-thirty-little" class="articlebottom">Chen et al., “Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3,” J. Neurosci., vol. 28, no. 48, pp. 12713–12724, Nov. 2008.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663415/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jneurosci.org/content/28/48/12713.long" class="links">[JNeurosci - Full Text]</a></li>
          <li><a id="ref-thirty-one-little" class="articlebottom">Pellistri et al., “Different ataxin-3 amyloid aggregates induce intracellular Ca(2+) deregulation by different mechanisms in cerebellar granule cells,” Biochim. Biophys. Acta, vol. 1833, no. 12, pp. 3155–3165, Dec. 2013.</a><br><a href="https://www.sciencedirect.com/science/article/pii/S0167488913003182?via%3Dihub" class="links">[ScienceDirect - Full Text]</a></li>
          <li><a id="ref-thirty-two-little" class="articlebottom">Zhivotovsky and S. Orrenius, “Calcium and cell death mechanisms: a perspective from the cell death community,” Cell Calcium, vol. 50, no. 3, pp. 211–221, 2011.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/21459443/" class="links">[PUBMED]</a><a href="https://www.sciencedirect.com/science/article/abs/pii/S0143416011000522?via%3Dihub" class="links">[ScienceDirect]</a></li>
          <li><a id="ref-thirty-three-little" class="articlebottom">H. Koeppen, “The Neuropathology of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease,” Adv. Exp. Med. Biol., vol. 1049, pp. 233–241, 2018.</a><br><a href="https://www.researchgate.net/publication/350234979_The_cerebellar_cognitive_affective_syndrome_scale_reveals_early_neuropsychological_deficits_in_SCA3_patients" class="links">[ResearchGate - Full Text]</a></li>
          <li><a id="ref-thirty-four-little" class="articlebottom">Paulson, “Machado-Joseph Disease/Spinocerebellar Ataxia Type 3,” Handb. Clin. Neurol. / Ed. by P.J. Vinken G.W. Bruyn, vol. 103, p. 437, 2012.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568768/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a id="ref-thirty-five-little" class="articlebottom">N. Rosenberg, “Machado-Joseph disease: an autosomal dominant motor system degeneration,” Mov. Disord., vol. 7, no. 3, pp. 193–203, 1992.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/1620135/" class="links">[PUBMED]</a><a href="https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.870070302" class="links">
            [Moviment Disorders]</a></li>
        </ol>
      </div>
    </section>
    </div>
    <div class="aside-bar-right" id="bar-right">
      <div class="ref-side-bar">
        <h3><i class="fa-solid fa-link"></i> References</h3>
        <ul>
          <li><a href="" id="ref-one" class="articlefocus">1. &nbsp A. T. Meira, J. L. Pedroso, F. Boller, G. L. Franklin, O. G. P. Barsottini, and H. A. G. Teive, “Reconstructing the History of Machado-Joseph Disease,” Eur. Neurol., vol. 83, no. 1, pp. 99–104, May 2020.</a><br><a href="https://www.karger.com/Article/FullText/507191" class="links">[Karger - Full Text]</a></li>
          <li><a href="" id="ref-two" class="articlefocus">2. &nbsp L. Lima and P. Coutinho, “Clinical criteria for diagnosis of Machado‐Joseph disease,” Neurology, vol. 30, no. 3, pp. 319–319, Mar. 1980.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/7189034/" class="links">[PUBMED]</a><a href="https://n.neurology.org/content/30/3/319" class="links">[Neurology]</a></li>
          <li><a href="" id="ref-three" class="articlefocus">3. &nbsp T. Klockgether, C. Mariotti, and H. L. Paulson, “Spinocerebellar ataxia,” Nat. Rev. Dis. Prim., vol. 5, no. 1, Dec. 2019.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/30975995/" class="links">[PUBMED]</a><a href="https://www.nature.com/articles/s41572-019-0074-3" class="links">[Nature]</a></li>
          <li><a href="" id="ref-four" class="articlefocus">4. &nbsp H. Paulson and V. Shakkottai, “Spinocerebellar Ataxia Type 3,” GeneReviews®, Jun. 2020, Accessed: Mar. 08, 2022. [Online]. Available:</a><br><a href="https://www.ncbi.nlm.nih.gov/books/NBK1196/" class="links">[NCBI Books]</a></li>
          <li><a href="" id="ref-five" class="articlefocus">5. &nbsp C. N. C. Matos, L. Pereira de Almeida, “Polyglutamine Disorders,” J. Neurochem., vol. 1049, no. September, pp. 255–273, 2018.</a><br><a href="https://link.springer.com/book/10.1007/978-3-319-71779-1" class="links"></a></li>
          <li><a href="" id="ref-six" class="articlefocus">6. &nbsp C. Bettencourt and M. Lima, “Machado-Joseph disease: From first descriptions to new perspectives,” Orphanet J. Rare Dis., vol. 6, no. 1, 2011.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123549/" class="links">[PUBMED Central - Full Text]</a><a href="https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-6-35" class="links">[BMC - Full Text]</a></li>
          <li><a href="" id="ref-seven" class="articlefocus">7. &nbsp M. M. Evers, L. J. A. Toonen, and W. M. C. Van Roon-Mom, “Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies,” Mol. Neurobiol., vol. 49, no. 3, p. 1513, 2014.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012159/" class="links">[PUBMED Central - Full Text]</a><a href="https://link.springer.com/article/10.1007/s12035-013-8596-2" class="links">[Springer - Full Text]</a></li>
          <li><a href="" id="ref-eight" class="articlefocus">8. &nbsp M. N. Laço, L. Cortes, S. M. Travis, H. L. Paulson, and A. C. Rego, “Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3,” PLoS One, vol. 7, no. 9, Sep. 2012.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435318/" class="links">[PUBMED Central - Full Text]</a><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043563" class="links">[PLOS One - Full Text]</a></li>
          <li><a href="" id="ref-nine" class="articlefocus">9. &nbsp J. J. Bai, S. S. Safadi, P. Mercier, K. R. Barber, and G. S. Shaw, “Ataxin-3 is a multivalent ligand for the parkin Ubl domain,” Biochemistry, vol. 52, no. 42, pp. 7369–7376, Oct. 2013.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807529/" class="links">[PUBMED Central - Full Text]</a><a href="https://pubs.acs.org/doi/10.1021/bi400780v" class="links">[ACS - Full Text]</a></li>
          <li><a href="" id="ref-ten" class="articlefocus">10. &nbsp K. M. Bernardi, J. M. Williams, T. Inoue, A. Schultz, and B. Tsai, “A deubiquitinase negatively regulates retro-translocation of nonubiquitinated substrates,” Mol. Biol. Cell, vol. 24, no. 22, pp. 3545–3556, Nov. 2013.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826992/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.molbiolcell.org/doi/10.1091/mbc.E13-06-0332?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed" class="links">[MBoC - Full Text]</a></li>
          <li><a href="" id="ref-eleven" class="articlefocus">11. &nbsp Q. Wang, A. Li, and Y. Ye, “Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3,” J. Cell Biol., vol. 174, no. 7, pp. 963–971, Sep. 2006.</a><br><a href="https://rupress.org/jcb/article/174/7/963/44580/Regulation-of-retrotranslocation-by-p97-associated" class="links">[JCB - Full Text]</a></li>
          <li><a href="" id="ref-twelve" class="articlefocus">12. &nbsp T. Klockgether, “Ataxias,” Textb. Clin. Neurol. Third Ed., pp. 765–780, Jan. 2007.</a><br><a href="https://www.sciencedirect.com/science/article/abs/pii/S1353802008700361" class="links">[ScienceDirect]</a></li>
          <li><a href="" id="ref-thirteen" class="articlefocus">13. &nbsp A. J. Rodrigues et al., “Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death,” Biochim. Biophys. Acta, vol. 1803, no. 10, pp. 1154–1163, Oct. 2010.</a><br><a href="https://www.sciencedirect.com/science/article/pii/S0167488910001989?via%3Dihub" class="links">[ScienceDirect - Full Text]</a></li>
          <li><a href="" id="ref-fourteen" class="articlefocus">14. &nbsp L. Schöls, A. M. M. Vieira-saecker, S. Schöls, H. Przuntek, J. T. Epplen, and O. Riess, “Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients,” Hum. Mol. Genet., vol. 4, no. 6, pp. 1001–1005, Jun. 1995.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/7655453/" class="links">[PUBMED]</a><a href="https://academic.oup.com/hmg/article-abstract/4/6/1001/627632?redirectedFrom=fulltext" class="links">[Oxford Academic]</a></li>
          <li><a href="" id="ref-fifteen" class="articlefocus">15. &nbsp G. H. Wang, N. Sawai, S. Kotliarova, I. Kanazawa, and N. Nukina, “Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B,” Hum. Mol. Genet., vol. 9, no. 12, pp. 1795–1803, 2000.</a><br><a href="https://academic.oup.com/hmg/article/9/12/1795/578314" class="links">[Oxford Academic]</a></li>
          <li><a href="" id="ref-sixteen" class="articlefocus">16. &nbsp D. Tait et al., “Ataxin-3 is transported into the nucleus and associates with the nuclear matrix,” Hum. Mol. Genet., vol. 7, no. 6, pp. 991–997, Jun. 1998.</a><br><a href="https://academic.oup.com/hmg/article/7/6/991/2896786?login=false" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-seventeen" class="articlefocus">17. &nbsp S. Macedo-Ribeiro, L. Cortes, P. Maciel, and A. L. Carvalho, “Nucleocytoplasmic Shuttling Activity of Ataxin-3,” PLoS One, vol. 4, no. 6, p. e5834, Jun. 2009.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688764/" class="links">[PUBMED Central - Full Text]</a><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005834" class="links">[PLOS One - Full Text]</a></li>
          <li><a href="" id="ref-eighteen" class="articlefocus">18. &nbsp M. Arrasate, S. Mitra, E. S. Schweitzer, M. R. Segal, and S. Finkbeiner, “Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death,” Nature, vol. 431, no. 7010, pp. 805–810, Oct. 2004.</a><br><a href="https://www.nature.com/articles/nature02998" class="links">[Nature - Full Text]</a></li>
          <li><a href="" id="ref-nineteen" class="articlefocus">19. &nbsp C. A. Ross and M. A. Poirier, “Protein aggregation and neurodegenerative disease,” Nat. Med., vol. 10 Suppl, no. 7, p. S10, 2004.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/15272267/" class="links">[PUBMED]</a><a href="https://www.nature.com/articles/nm1066" class="links">[Nature]</a></li>
          <li><a href="" id="ref-twenty" class="articlefocus">20. &nbsp H. Olzscha et al., “Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions,” Cell, vol. 144, no. 1, pp. 67–78, Jan. 2011.</a><br><a href="https://www.cell.com/cell/fulltext/S0092-8674(10)01372-3" class="links">[Cell - Full Text]</a></li>
          <li><a href="" id="ref-twenty-one" class="articlefocus">21. &nbsp A. McCampbell et al., “CREB-binding protein sequestration by expanded polyglutamine,” Hum. Mol. Genet., vol. 9, no. 14, pp. 2197–2202, Sep. 2000.</a><br><a href="https://academic.oup.com/hmg/article/9/14/2197/614727" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-twenty-two" class="articlefocus">22. &nbsp H. L. Paulson et al., “Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3,” Neuron, vol. 19, no. 2, pp. 333–344, 1997.</a><br><a href="https://www.sciencedirect.com/science/article/pii/S0896627300809435" class="links">[ScienceDirect - Full Text]</a></li>
          <li><a href="" id="ref-twenty-three" class="articlefocus">23. &nbsp H. S. McLoughlin, L. R. Moore, and H. L. Paulson, “Pathogenesis of SCA3 and implications for other polyglutamine diseases,” Neurobiol. Dis., vol. 134, p. 104635, Feb. 2020.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980715/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.sciencedirect.com/science/article/pii/S0969996119303109?via%3Dihub" class="links">[ScienceDirect - Full Text]</a></li>
          <li><a href="" id="ref-twenty-four" class="articlefocus">24. &nbsp A. D’Abreu, M. C. França, H. L. Paulson, and I. Lopes-Cendes, “Caring for Machado-Joseph disease: current understanding and how to help patients,” Parkinsonism Relat. Disord., vol. 16, no. 1, pp. 2–7, Jan. 2010.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818316/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-twenty-five" class="articlefocus">25. &nbsp A. Ashkenazi et al., “Polyglutamine tracts regulate beclin 1-dependent autophagy,” Nature, vol. 545, no. 7652, pp. 108–111, May 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420314/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-twenty-six" class="articlefocus">26. &nbsp A. Pfeiffer et al., “Ataxin-3 consolidates the MDC1-dependent DNA double-strand break response by counteracting the SUMO-targeted ubiquitin ligase RNF4,” EMBO J., vol. 36, no. 8, pp. 1066–1083, Apr. 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391139/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.embopress.org/doi/full/10.15252/embj.201695151" class="links">[EMBOpress - Full Text]
          </a></li>
          <li><a href="" id="ref-twenty-seven" class="articlefocus">27. &nbsp A. H. Chou et al., “Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL,” Neurobiol. Dis., vol. 21, no. 2, pp. 333–345, Feb. 2006.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/16112867/" class="links">[PUBMED]</a><a href="https://www.sciencedirect.com/science/article/abs/pii/S0969996105002123?via%3Dihub" class="links">[ScienceDirect]</a></li>
          <li><a href="" id="ref-twenty-eight" class="articlefocus">28. &nbsp H. F. Tsai, H. J. Tsai, and M. Hsieh, “Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells,” Biochem. Biophys. Res. Commun., vol. 324, no. 4, pp. 1274–1282, Nov. 2004.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/15504352/" class="links">[PUBMED]</a><a href="https://www.sciencedirect.com/science/article/abs/pii/S0006291X04022223?via%3Dihub" class="links">[ScienceDirect]</a></li>
          <li><a href="" id="ref-twenty-nine" class="articlefocus">29. &nbsp Y. C. Yu, C. L. Kuo, W. L. Cheng, C. S. Liu, and M. Hsieh, “Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease,” J. Neurosci. Res., vol. 87, no. 8, pp. 1884–1891, 2009.</a><br><a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/jnr.22011" class="links">[Wiley Online Library]</a></li>
          <li><a href="" id="ref-thirty" class="articlefocus">30. &nbsp X. Chen et al., “Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3,” J. Neurosci., vol. 28, no. 48, pp. 12713–12724, Nov. 2008.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663415/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jneurosci.org/content/28/48/12713.long" class="links">[JNeurosci - Full Text]</a></li>
          <li><a href="" id="ref-thirty-one" class="articlefocus">31. &nbsp F. Pellistri et al., “Different ataxin-3 amyloid aggregates induce intracellular Ca(2+) deregulation by different mechanisms in cerebellar granule cells,” Biochim. Biophys. Acta, vol. 1833, no. 12, pp. 3155–3165, Dec. 2013.</a><br><a href="https://www.sciencedirect.com/science/article/pii/S0167488913003182?via%3Dihub" class="links">[ScienceDirect - Full Text]</a></li>
          <li><a href="" id="ref-thirty-two" class="articlefocus">32. &nbsp B. Zhivotovsky and S. Orrenius, “Calcium and cell death mechanisms: a perspective from the cell death community,” Cell Calcium, vol. 50, no. 3, pp. 211–221, 2011.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/21459443/" class="links">[PUBMED]</a><a href="https://www.sciencedirect.com/science/article/abs/pii/S0143416011000522?via%3Dihub" class="links">[ScienceDirect]</a></li>
          <li><a href="" id="ref-thirty-three" class="articlefocus">33. &nbsp A. H. Koeppen, “The Neuropathology of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease,” Adv. Exp. Med. Biol., vol. 1049, pp. 233–241, 2018.</a><br><a href="https://www.researchgate.net/publication/350234979_The_cerebellar_cognitive_affective_syndrome_scale_reveals_early_neuropsychological_deficits_in_SCA3_patients" class="links">[ResearchGate - Full Text]</a></li>
          <li><a href="" id="ref-thirty-four" class="articlefocus">34. &nbsp H. Paulson, “Machado-Joseph Disease/Spinocerebellar Ataxia Type 3,” Handb. Clin. Neurol. / Ed. by P.J. Vinken G.W. Bruyn, vol. 103, p. 437, 2012.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568768/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-thirty-five" class="articlefocus">35. &nbsp R. N. Rosenberg, “Machado-Joseph disease: an autosomal dominant motor system degeneration,” Mov. Disord., vol. 7, no. 3, pp. 193–203, 1992.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/1620135/" class="links">[PUBMED]</a><a href="https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.870070302" class="links">[Moviment Disorders]</a></li>
        </ul>
      </div>
    </div>
  </main>
  <footer id=footer>
    <div class="collumns">
      <div class="first-third">
        <ul>
          <li><a href="../../">Landing Page</a></li>
          <li><a href="https://abcri.pt/">ABC-RI</a></li>
          <li><a href="https://abcri.pt/research-groups/clevio-nobrega/#menu">MNGT group</a></li>
          <li><a href="https://abcri.pt/news/">ABC-RI News</a></li>
        </ul>
      </div>
      <div class="second-third">
        <ul>
          <li><a href="../../authors">Authors</a></li>
          <li><a href="https://www.ualg.pt/">UAlg</a></li>
          <li><a href="https://fmcb.ualg.pt/en">UAlg - FMCB</a></li>
          <li><a href="https://fmcb.ualg.pt/en/master-biomedical-sciences">Masters degree</a></li>
        </ul>
      </div>
      <div class="third-third">
        <ul>
          <li><a href="../../contact">Contact</a></li>
          <li><a href="../../objectives">Objectives</a></li>
          <li><a href="../../appreciation">Appreciation</a></li>
        </ul>
      </div>
    </div>
    <svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="200.000000pt" height="200.000000pt" viewBox="0 0 200.000000 200.000000" preserveAspectRatio="xMidYMid meet">
<metadata>
Created by potrace 1.10, written by Peter Selinger 2001-2011
</metadata>
<g transform="translate(0.000000,200.000000) scale(0.100000,-0.100000)" fill="#3d85c6" stroke="none">
<path d="M1514 1622 c-11 -10 -31 -22 -44 -25 -38 -10 -45 -17 -84 -82 -40 -67 -44 -94 -20 -135 18 -29 101 -80 132 -80 10 0 23 -5 29 -11 6 -6 26 -14 43 -18 24 -4 38 -16 51 -40 10 -19 23 -39 28 -44 14 -14 61 19 61 43 0 12 10 25 23 30 36 15 78 65 89 107 20 79 20 89 -8 152 -25 55 -33 64 -83 90 -72 36 -185 42 -217 13z m76 -27 c-10 -12 -10 -19 -2 -27 9 -9 18 -4 37 16 14 15 28 25 33 23 4 -2 25 -12 47 -22 40 -18 75 -43 75 -54 0 -9 -67 -7 -76 2 -12 12 -44 8 -44 -5 0 -20 48 -38 81 -31 49 9 81 -33 63 -81 -7 -19 -36 -21 -65 -3 -17 9 -23 9 -26 0 -3 -8 -14 -11 -28 -7 -12 3 -26 1 -30 -5 -3 -6 -17 -8 -31 -5 -13 3 -24 2 -24 -4 0 -19 -33 -22 -57 -6 -35 22 -52 3 -23 -24 21 -20 21 -20 2 -26 -23 -8 -117 37 -126 60 -9 24 -7 74 3 74 5 0 11 -7 15 -15 9 -26 48 -17 77 18 21 24 28 28 29 15 0 -24 22 -23 38 2 7 11 21 20 31 20 11 0 22 4 26 9 10 17 -15 23 -68 16 -38 -6 -58 -15 -78 -37 -25 -26 -29 -27 -37 -11 -19 32 20 83 64 83 8 0 23 9 34 20 11 11 32 20 46 20 23 0 25 -2 14 -15z m179 -224 l34 -1 -23 -25 c-25 -26 -59 -32 -91 -15 -15 8 -24 6 -41 -10 -13 -11 -35 -20 -54 -20 -60 0 -53 30 11 50 22 7 46 15 53 19 8 3 28 5 45 5 18 -1 47 -2 66 -3z m-34 -81 c-3 -5 -12 -10 -20 -10 -8 0 -17 5 -20 10 -4 6 5 10 20 10 15 0 24 -4 20 -10z m-61 -22 c14 -55 0 -64 -26 -19 -12 22 -13 31 -5 35 21 8 25 6 31 -16z"/>
<path d="M72 1198 c-23 -23 -14 -59 18 -71 l30 -11 0 -163 c0 -150 -1 -163 -18 -163 -37 0 -57 -51 -30 -78 15 -15 100 -15 152 -1 60 16 158 119 182 189 32 94 68 153 113 187 23 18 48 33 54 33 9 0 12 -46 12 -165 0 -91 -1 -165 -2 -165 -1 0 -13 5 -27 11 -25 12 -25 14 -28 142 l-3 130 -29 -41 c-25 -37 -28 -48 -24 -102 4 -63 -4 -78 -19 -34 -9 26 -10 26 -36 -27 l-26 -54 31 -33 c81 -83 206 -106 306 -56 81 40 129 104 177 238 20 54 73 119 117 142 l28 15 0 -166 0 -165 -22 11 c-22 10 -23 13 -20 139 3 142 -1 151 -48 88 -19 -26 -22 -40 -18 -94 2 -35 3 -64 1 -64 -1 0 -8 12 -16 26 l-14 26 -26 -53 -26 -54 32 -34 c92 -97 257 -108 353 -24 44 39 93 115 114 177 27 82 69 140 120 166 l40 20 0 -164 0 -165 -22 8 c-22 8 -23 15 -28 137 l-5 128 -29 -34 c-26 -31 -28 -39 -24 -97 4 -66 -4 -82 -19 -37 -9 26 -10 26 -36 -27 l-26 -54 32 -33 c52 -55 116 -82 191 -82 56 0 67 3 76 21 9 16 8 26 -5 45 -8 13 -22 24 -30 24 -13 0 -15 26 -15 164 0 152 1 164 19 169 31 8 43 40 25 65 -13 18 -25 22 -72 22 -131 0 -232 -90 -286 -256 -19 -57 -73 -127 -117 -149 -15 -8 -30 -15 -34 -15 -3 0 -5 74 -5 165 0 91 3 165 6 165 3 0 14 -5 25 -10 17 -10 19 -22 19 -143 l0 -132 28 28 c23 24 28 37 32 105 6 73 6 75 18 48 l13 -30 25 54 25 53 -38 39 c-54 55 -107 78 -181 78 -112 0 -206 -69 -259 -188 -13 -31 -34 -78 -45 -104 -21 -48 -51 -82 -100 -113 l-28 -17 0 166 c0 164 0 167 20 156 18 -10 20 -21 20 -143 l1 -132 36 39 c35 38 35 39 29 102 -7 69 -2 81 15 37 l11 -28 23 45 c32 61 31 73 -12 110 -114 100 -276 92 -375 -18 -42 -47 -63 -83 -89 -159 -10 -30 -28 -67 -40 -84 -22 -31 -94 -89 -111 -89 -4 0 -8 74 -8 165 0 91 3 165 6 165 3 0 14 -5 25 -10 17 -10 19 -23 19 -143 l1 -132 29 34 c25 30 30 44 32 105 3 68 4 70 17 44 l14 -27 23 50 c22 46 22 52 8 74 -17 27 -76 69 -117 84 -38 15 -140 14 -155 -1z m153 -22 c19 -8 51 -27 70 -42 50 -38 44 -69 -17 -88 -15 -4 -18 -17 -18 -71 0 -37 -4 -64 -9 -61 -5 3 -9 41 -9 83 0 43 -1 86 -1 95 -1 25 -58 53 -77 37 -19 -15 -21 -318 -2 -337 24 -24 57 -12 107 36 37 36 56 66 81 130 18 46 46 101 62 123 36 49 111 106 117 87 2 -7 10 -21 19 -30 14 -16 13 -18 -6 -18 -48 0 -103 -73 -151 -199 -26 -69 -84 -143 -133 -171 -48 -27 -161 -40 -173 -20 -5 9 3 22 24 39 l31 26 0 160 0 160 -31 26 c-19 15 -29 31 -25 37 10 17 100 15 141 -2z m487 -12 c18 -9 47 -30 65 -47 26 -24 30 -34 22 -49 -5 -10 -21 -18 -34 -18 -27 0 -33 -13 -38 -95 -2 -27 -4 -8 -5 44 -2 82 -5 98 -24 118 -25 27 -41 29 -62 7 -23 -23 -23 -315 0 -338 20 -20 20 -20 69 8 51 30 85 78 124 174 37 92 62 129 115 168 54 41 108 58 162 50 86 -11 172 -74 159 -116 -4 -13 -13 -20 -24 -18 -10 2 -25 -3 -34 -11 -15 -12 -17 -10 -17 22 0 27 -7 41 -27 57 -32 25 -54 23 -68 -6 -10 -21 -10 -21 -28 3 -22 28 -45 24 -91 -14 -46 -38 -81 -93 -106 -164 -41 -119 -116 -192 -215 -210 -87 -16 -126 9 -70 45 25 16 25 17 25 180 l0 164 -27 20 c-18 13 -24 24 -20 36 6 15 16 17 62 12 30 -3 70 -13 87 -22z m898 10 c2 -3 -9 -16 -25 -28 -30 -23 -30 -26 -33 -127 -2 -57 -5 -106 -8 -108 -2 -2 -4 43 -4 101 0 123 -9 139 -60 118 -46 -19 -112 -99 -134 -161 -25 -72 -68 -148 -103 -181 -85 -81 -235 -83 -312 -4 -25 25 -31 39 -26 55 3 12 14 21 24 21 28 0 41 21 43 70 1 26 4 11 7 -39 6 -77 8 -86 33 -104 27 -20 28 -20 48 -2 18 16 20 32 22 159 l2 141 6 -149 c6 -178 11 -185 85 -142 52 31 95 91 121 170 49 145 154 231 269 219 22 -3 42 -7 45 -9z m-1072 -380 c20 -10 21 -13 7 -24 -8 -7 -15 -19 -15 -27 0 -11 -6 -11 -30 4 -17 10 -42 30 -56 44 -22 23 -23 29 -13 52 7 15 17 23 25 20 28 -11 44 18 46 81 1 46 3 37 7 -39 6 -91 8 -100 29 -111z m912 44 c0 -55 51 -88 80 -53 11 13 16 12 41 -8 50 -39 30 -62 -44 -51 -51 8 -102 34 -139 69 -23 21 -26 29 -16 44 6 11 19 16 29 14 11 -3 21 1 25 11 9 24 24 9 24 -26z"/>
<path d="M470 550 c0 -65 3 -90 13 -90 9 0 11 23 9 90 -2 49 -8 90 -13 90 -5 0 -9 -40 -9 -90z"/>
<path d="M1090 551 l0 -89 33 1 c31 2 32 3 35 55 3 56 -10 85 -34 75 -10 -4 -14 2 -14 21 0 14 -4 26 -10 26 -6 0 -10 -36 -10 -89z m48 -27 c-2 -22 -7 -39 -13 -39 -12 0 -19 60 -10 83 10 28 27 -3 23 -44z"/>
<path d="M280 545 c0 -69 3 -85 15 -85 9 0 15 9 15 25 0 15 6 25 15 25 19 0 35 31 35 69 0 32 -22 51 -59 51 -20 0 -21 -6 -21 -85z m50 19 c0 -19 -4 -34 -10 -34 -5 0 -10 18 -10 41 0 24 4 38 10 34 6 -3 10 -22 10 -41z"/>
<path d="M612 618 c-7 -7 -12 -38 -12 -70 0 -45 5 -66 22 -88 21 -29 58 -41 58 -20 0 6 -7 10 -17 10 -15 0 -15 1 0 18 12 13 17 37 17 78 0 61 -11 84 -40 84 -9 0 -21 -5 -28 -12z m46 -85 c-5 -72 -28 -68 -28 5 0 32 3 62 7 66 13 13 24 -24 21 -71z"/>
<path d="M750 545 c0 -83 0 -85 24 -85 39 0 56 25 56 84 0 58 -19 86 -58 86 -21 0 -22 -4 -22 -85z m45 0 c0 -38 -4 -60 -12 -62 -10 -4 -13 13 -13 62 0 49 3 66 13 63 8 -3 12 -25 12 -63z"/>
<path d="M939 608 c-3 -53 3 -134 11 -142 5 -5 17 -5 27 -1 17 8 17 8 1 12 -25 6 -26 91 -2 100 15 6 15 7 -1 19 -9 7 -14 17 -10 23 3 6 -1 11 -9 11 -10 0 -17 -9 -17 -22z"/>
<path d="M392 591 c-19 -11 -27 -83 -13 -110 15 -26 47 -27 61 -2 15 29 12 87 -6 105 -18 18 -24 19 -42 7z m28 -61 c0 -27 -4 -50 -10 -50 -5 0 -10 23 -10 50 0 28 5 50 10 50 6 0 10 -22 10 -50z"/>
<path d="M510 588 c0 -7 7 -40 15 -73 12 -52 12 -61 0 -71 -20 -15 -19 -24 5 -24 19 0 28 22 45 110 4 19 9 43 11 53 4 11 0 17 -10 17 -11 0 -16 -9 -16 -29 0 -16 -3 -38 -7 -48 -6 -13 -9 -6 -13 26 -3 25 -11 46 -17 49 -7 2 -13 -2 -13 -10z"/>
<path d="M852 588 c-13 -13 -16 -38 -6 -38 4 0 13 8 20 18 12 16 13 16 20 -2 5 -13 3 -21 -4 -24 -24 -8 -43 -35 -40 -56 2 -16 11 -21 36 -23 l32 -1 0 63 c0 48 -4 64 -16 69 -22 8 -28 8 -42 -6z m38 -88 c0 -19 -11 -26 -23 -14 -8 8 3 34 14 34 5 0 9 -9 9 -20z"/>
<path d="M1006 584 c-20 -20 -20 -34 -1 -34 8 0 15 7 15 15 0 8 5 15 10 15 19 0 10 -31 -16 -54 -37 -31 -26 -66 20 -66 l33 0 -4 58 c-3 31 -6 63 -8 70 -6 17 -30 15 -49 -4z m34 -84 c0 -11 -4 -20 -10 -20 -5 0 -10 9 -10 20 0 11 5 20 10 20 6 0 10 -9 10 -20z"/>
<path d="M1193 593 c-13 -5 -18 -43 -7 -43 4 0 13 8 20 18 12 16 13 16 14 0 0 -9 -11 -29 -25 -42 -33 -33 -21 -65 25 -64 30 1 30 2 30 58 0 69 -16 90 -57 73z m23 -110 c-11 -11 -19 6 -11 24 8 17 8 17 12 0 3 -10 2 -21 -1 -24z"/>
<path d="M1271 581 c-8 -15 -5 -27 15 -56 25 -37 26 -65 0 -30 -9 13 -15 15 -20 6 -11 -17 14 -42 38 -39 29 4 32 35 7 69 -12 15 -21 34 -21 41 1 8 5 7 14 -4 17 -23 26 -23 26 1 0 17 -18 31 -40 31 -5 0 -14 -9 -19 -19z"/>
<path d="M1362 588 c-7 -7 -12 -36 -12 -65 0 -57 17 -76 48 -56 22 13 27 33 8 33 -9 0 -16 -4 -16 -10 0 -5 -4 -10 -10 -10 -5 0 -10 9 -10 20 0 15 7 20 25 20 21 0 25 5 25 28 0 29 -16 52 -35 52 -6 0 -16 -5 -23 -12z m38 -40 c0 -5 -7 -8 -15 -8 -15 0 -20 21 -8 33 7 7 23 -11 23 -25z"/>
</g>
</svg>
    <p> &copyPolyQ Database. All rights reserved 2021-2022. Authors mentioned and database creators all accounted for.</p>
    <div class="logos">
      <a class="logo-one"> <img src="../../Images/Logo_ABCRI.png" alt=""></a>
      <a class="logo-two"> <img src="../../Images/Logo_MNGT.png" alt=""></a>
      <a class="logo-three"> <img src="../../Images/fmcb-mod.png" alt=""></a>
    </div>
  </footer>
  <script src="../../Scripts/jquery-3.6.0.min.js"></script>
  <script src="../../Scripts/interactive-image.min.js"></script>
  <script src="../../Scripts/Image-Int-Scripts/image-int-sca3.js"></script>
  <script>
            var indicator = document.getElementById('indicator');

            var spy = new ScrollSpy(
                {
                    contexts_class: 'scrollspy'
                }
            );

            spy.Indicator({
                element: indicator
            });
</script>
<script>
/* When the user clicks on the button,
toggle between hiding and showing the dropdown content */
function myFunction() {
  document.getElementById("myDropdown").classList.toggle("show");
}

function myFunctionLittle() {
  document.getElementById("myDropdownLittle").classList.toggle("show");
}

// Close the dropdown if the user clicks outside of it
window.onclick = function(event) {
  if (!event.target.matches('.dropbtn')) {
    var dropdowns = document.getElementsByClassName("dropdown-content");
    var i;
    for (i = 0; i < dropdowns.length; i++) {
      var openDropdown = dropdowns[i];
      if (openDropdown.classList.contains('show')) {
        openDropdown.classList.remove('show');
      }
    }
  }
  if (!event.target.matches('.dropbtn-little')){
    var dropLittle = document.getElementsByClassName("dropdown-content-little");
    var r;
    for (r = 0; r < dropLittle.length; r++) {
      var openDropLittle = dropLittle[r];
      if (openDropLittle.classList.contains('show')) {
        openDropLittle.classList.remove('show');
      }
    }
  }
}

</script>
<script>


$(document).scroll(function() {
    checkOffset();
});

function checkOffset() {
    if($('#bar-right').offset().top + $('#bar-right').height() >= $('#references').offset().top + 200)
          $('#bar-right').hide(800);
    if($(document).scrollTop() + window.innerHeight < $('#references').offset().top + 200)
          $('#bar-right').show(800); // restore when you scroll up
}
</script>
<script>

function reload(){
  var imageInt = document.getElementById("my-interactive-image");
  var imageContent = imageInt.innerHTML;
  imageInt.innerHTML = imageContent;
}

</script>


</body>


</html>
